Yükleniyor... / Loading...
This study examines Erdafitinib in patients with advanced solid tumors carrying FGFR gene mutations or gene fusions. Patients with unresectable, locally advanced, or metastatic solid tumors who received at least one prior systemic therapy could take part. It was conducted in Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
+139
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Histologic demonstration of an unresectable, locally advanced, or metastatic solid tumor malignancy with an fibroblast growth factor receptor (FGFR) mutation or FGFR gene fusion * Measurable disease * Participant must have received at least one prior line of systemic therapy in the advanced, unresectable, or metastatic setting; or is a child or adolescent participant with a newly-diagnosed solid tumor and no acceptable standard therapies * Documented progression of disease, defined as any progression that requires a change in treatment, prior to full study screening Exclusion Criteria: * Has had prior chemotherapy, targeted therapy, or treatment with an investigational anticancer agent within 15 days or less than or equal to (\<=) 5 half-lives of the agent (whichever is longer) and up to a maximum of 30 days before the first dose of erdafitinib * The presence of FGFR gatekeeper and resistance mutations * Histologic demonstration of urothelial carcinoma * Hematologic malignancy (i.e., myeloid and lymphoid neoplasms * For non-small cell lung cancer participants only: pathogenic somatic mutations or gene fusions in the following genes: EGFR, ALK, ROS1, NTRK, BRAF V600E and KRAS * Active malignancies other than for disease requiring therapy